

INPLASY PROTOCOL

To cite: Dai et al. Clinical effect of mifepristone combined with Guizhi Fuling capsule in the treatment of uterine fibroids: a meta analysis. Inplasy protocol 202230170. doi: 10.37766/inplasy2022.3.0170

Received: 30 March 2022

Published: 30 March 2022

Corresponding author:
Xiaoxia Dai

2572276958@qq.com

Author Affiliation:
Hubei University of Medicine.

Support: WU.

Review Stage at time of this submission: The review has not yet started.

Conflicts of interest:
None declared.

Clinical effect of mifepristone combined with Guizhi Fuling capsule in the treatment of uterine fibroids: a meta analysis

Dai, X¹; Liu, B²; Li, J³; Liu, X⁴.

Review question / Objective: Clinical effect of mifepristone combined with Guizhi Fuling capsule in the treatment of uterine fibroids: a meta analysis.

Eligibility criteria: Patients diagnosed as uterine fibroids by gynecology and B-ultrasound examination; Diseases of the heart, lung and kidney; Not taking hormones for at least 3 months; Patients' age, batch number, frequency, dosage and course of medication were not limited.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 30 March 2022 and was last updated on 30 March 2022 (registration number INPLASY202230170).

INTRODUCTION

Review question / Objective: Clinical effect of mifepristone combined with Guizhi Fuling capsule in the treatment of uterine fibroids: a meta analysis.

Condition being studied: Uterine fibroids.

METHODS

Participant or population: Patients diagnosed as uterine fibroids by gynecology and B-ultrasound examination.

Intervention: Mifepristone combined with Guizhi Fuling.

Comparator: Mifepristone.

Study designs to be included: RCT.

Eligibility criteria: Patients diagnosed as uterine fibroids by gynecology and B-ultrasound examination; Diseases of the heart, lung and kidney; Not taking hormones for at least 3 months; Patients' age, batch number, frequency, dosage and course of medication were not limited.

Information sources: Pubed, Embase, Cochrane Library, Wanfang, CNKI, VIP.

Main outcome(s): The clinical efficacy and safety of guizhi Poria capsule combined with mifepristone in the treatment of uterine fibroids are better than that of mifepristone alone.

Quality assessment / Risk of bias analysis: None of the included studies mentioned blinding and assignment hiding. Nine studies reported follow-up results at baseline, and five of them reported the rate of loss to follow-up without explanation of the cause or intentionality analysis.

Strategy of data synthesis: Revman.

Subgroup analysis: Duration and dose of medication.

Sensitivity analysis: Funnel plot

Country(ies) involved: China.

Keywords: Mifepristone; Guizhi Fuling capsules; uterus; fibroids.

Contributions of each author:

Author 1 - Xiaoxia Dai.

Author 2 - Bing Liu.

Author 3 - Juan Li.

Author 4 - Xiang Liu.